ArticleBMC gastroenterology2025
Development and validation of a nomogram for predicting early recurrence in patients undergoing different courses of postoperative adjuvant transarterial chemoembolisation.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is associated with a high rate of postoperative recurrence. Postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) is effective in preventing recurrence. However, the effect of different courses of PA-TACE on tumor prognosis remains unclear. As such, this study aimed to develop and validate a nomogram that incorporates different courses of PA-TACE to predict early tumor recurrence.
methodsData from 307 high-risk patients who underwent PA-TACE were divided into training and test cohorts at a 6:4 ratio. A nomogram was developed in the training group using least absolute shrinkage and selection operator (LASSO) regression to identify independent prognostic factors and subsequently tested in the test group. Patients were classified into high-, moderate-, and low-risk categories using X-tile software (Rimm Lab, Yale School of Medicine, New Haven, CT, USA), and survival was analyzed.
resultsA nomogram was developed based on independent prognostic factors, including age, tumor diameter, multiplicity, satellite nodules, PA-TACE course, and aspartate transaminase (AST) level. The nomogram demonstrated strong discriminatory power in the training cohort (C-index 0.718, 95% confidence interval [CI]: 0.672-0.763) and validated in a test cohort (C-index 0.759, 95% CI: 0.701-0.817). Calibration and decision curve analyses confirmed predictive accuracy and clinical utility. Kaplan-Meier curves revealed significant discriminatory power among the high-, moderate-, and low-risk groups. No significant differences in PA-TACE-related adverse reactions were observed across the treatment courses, except for allergic reactions.
conclusionThis study developed and validated a nomogram that accurately predicted the risk for early recurrence after PA-TACE treatment in patients with HCC at a high risk for recurrence. Importantly, the nomogram identified PA-TACE as a key prognostic factor with significant clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.